Literature DB >> 26019713

Thrombolysis in chinese ischemic stroke patients with renal dysfunction.

Wai Ting Lo1, Chi Yuen Cheung1, Chung Ki Li1, Ka Foon Chau1, Wing Chi Fong1.   

Abstract

BACKGROUND: Current data concerning the relationship between renal function and clinical outcome among stroke patients treated with intravenous thrombolytic therapy are conflicting. Our aim is to analyze whether the clinical outcome of Chinese ischemic stroke patients treated with thrombolytic therapy is affected by the presence of renal dysfunction.
METHODS: Chinese patients who received intravenous thrombolytic therapy for acute ischemic stroke were recruited. Renal dysfunction was defined as an estimated glomerular filtration rate (eGFR) <90 ml/min/1.73 m(2). The primary outcome was independent function (modified Rankin Scale, mRS, 0-2) at 3 months, while secondary outcomes included early improvement of the National Institute of Health Stroke Scale (NIHSS) score of ≥4 points at 24 h, symptomatic intracerebral hemorrhage (ICH) within 36 h of treatment and 30-day mortality.
RESULTS: A total of 199 patients were recruited, of whom 51.3% had renal dysfunction. There were no significant differences in functional independence at 3 months, NIHSS improvement at 24 h post-thrombolysis and 30-day mortality between patients with or without renal dysfunction. Multivariate analysis showed that eGFR as a continuous variable was not an independent risk factor for symptomatic ICH.
CONCLUSION: Chinese ischemic stroke patients with renal dysfunction who received thrombolytic therapy had clinical outcomes similar to those without renal dysfunction.

Entities:  

Keywords:  Intracerebral hemorrhage; Ischemic stroke; Renal dysfunction; Thrombolytic therapy

Year:  2015        PMID: 26019713      PMCID: PMC4439778          DOI: 10.1159/000375466

Source DB:  PubMed          Journal:  Interv Neurol        ISSN: 1664-5545


  28 in total

1.  Thrombolysis with alteplase for acute ischaemic stroke in the Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST): an observational study.

Authors:  Nils Wahlgren; Niaz Ahmed; Antoni Dávalos; Gary A Ford; Martin Grond; Werner Hacke; Michael G Hennerici; Markku Kaste; Sonja Kuelkens; Vincent Larrue; Kennedy R Lees; Risto O Roine; Lauri Soinne; Danilo Toni; Geert Vanhooren
Journal:  Lancet       Date:  2007-01-27       Impact factor: 79.321

2.  Racial differences in responses to thrombolytic therapy with recombinant tissue-type plasminogen activator. Increased fibrin(ogen)olysis in blacks. The Thrombolysis and Angioplasty in Myocardial Infarction Study Group.

Authors:  D C Sane; D C Stump; E J Topol; K N Sigmon; W K Clair; D J Kereiakes; B S George; M F Stoddard; E R Bates; R S Stack
Journal:  Circulation       Date:  1991-01       Impact factor: 29.690

Review 3.  Risks and benefits of antiplatelet therapy in uremic patients.

Authors:  Jeffrey B Washam; George L Adams
Journal:  Adv Chronic Kidney Dis       Date:  2008-10       Impact factor: 3.620

Review 4.  Disorders of hemostasis associated with chronic kidney disease.

Authors:  Diana I Jalal; Michel Chonchol; Giovanni Targher
Journal:  Semin Thromb Hemost       Date:  2010-04-13       Impact factor: 4.180

5.  Tissue plasminogen activator for acute ischemic stroke.

Authors: 
Journal:  N Engl J Med       Date:  1995-12-14       Impact factor: 91.245

6.  Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Second European-Australasian Acute Stroke Study Investigators.

Authors:  W Hacke; M Kaste; C Fieschi; R von Kummer; A Davalos; D Meier; V Larrue; E Bluhmki; S Davis; G Donnan; D Schneider; E Diez-Tejedor; P Trouillas
Journal:  Lancet       Date:  1998-10-17       Impact factor: 79.321

7.  Does renal dysfunction predict mortality after acute stroke? A 7-year follow-up study.

Authors:  Ronald S MacWalter; Suzanne Y S Wong; Kenneth Y K Wong; Graham Stewart; Callum G Fraser; Hazel W Fraser; Yuksel Ersoy; Simon A Ogston; Rouling Chen
Journal:  Stroke       Date:  2002-06       Impact factor: 7.914

8.  Kidney function is related to cerebral small vessel disease.

Authors:  M Arfan Ikram; Meike W Vernooij; Albert Hofman; Wiro J Niessen; Aad van der Lugt; Monique M B Breteler
Journal:  Stroke       Date:  2007-11-29       Impact factor: 7.914

9.  Renal dysfunction in acute stroke: an independent predictor of long-term all combined vascular events and overall mortality.

Authors:  George Tsagalis; Theodore Akrivos; Maria Alevizaki; Efstathios Manios; Kimon Stamatellopoulos; Antonis Laggouranis; Konstantinos N Vemmos
Journal:  Nephrol Dial Transplant       Date:  2008-08-26       Impact factor: 5.992

Review 10.  Renal dysfunction and thrombolytic therapy in patients with acute ischemic stroke: a systematic review and meta-analysis.

Authors:  Zilong Hao; Chunsong Yang; Ming Liu; Bo Wu
Journal:  Medicine (Baltimore)       Date:  2014-12       Impact factor: 1.889

View more
  2 in total

1.  Renal Dysfunction Is an Independent Risk Factor for Poor Outcome in Acute Ischemic Stroke Patients Treated with Intravenous Thrombolysis: A New Cutoff Value.

Authors:  Elyar Sadeghi-Hokmabadi; Demet Funda Baş; Mehdi Farhoudi; Aliakbar Taheraghdam; Daryoush Savadi Oskouei; Mohammad Yazdchi; Maziyar Hashemilar; Nevzat Uzuner; Reshad Mirnour; Ertugrul Colak; Atilla Özcan Özdemir
Journal:  Stroke Res Treat       Date:  2017-01-03

Review 2.  Clinical Variables and Genetic Risk Factors Associated with the Acute Outcome of Ischemic Stroke: A Systematic Review.

Authors:  Nuria P Torres-Aguila; Caty Carrera; Elena Muiño; Natalia Cullell; Jara Cárcel-Márquez; Cristina Gallego-Fabrega; Jonathan González-Sánchez; Alejandro Bustamante; Pilar Delgado; Laura Ibañez; Laura Heitsch; Jerzy Krupinski; Joan Montaner; Joan Martí-Fàbregas; Carlos Cruchaga; Jin-Moo Lee; Israel Fernandez-Cadenas
Journal:  J Stroke       Date:  2019-09-30       Impact factor: 6.967

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.